Drug Profile
DTP-poliovirus vaccine - Mitsubishi Tanabe Pharma
Alternative Names: BK-4SP; Diphtheria-toxoid tetanus-toxoid pertussis-PT-FHA-inactivated poliovirus combined vaccine; TetrabikLatest Information Update: 22 Aug 2017
Price :
$50
*
At a glance
- Originator Research Foundation for Microbial Diseases of Osaka University
- Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 26 Oct 2012 Launched for Diphtheria in Japan (SC)
- 26 Oct 2012 Launched for Pertussis in Japan (SC)
- 26 Oct 2012 Launched for Poliomyelitis in Japan (SC)